Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
147.8 USD | -1.06% | -1.08% | -22.79% |
Sales 2024 * | 1.87B 2.56B | Sales 2025 * | 2.26B 3.09B | Capitalization | 18.69B 25.53B |
---|---|---|---|---|---|
Net income 2024 * | -451M -616M | Net income 2025 * | -257M -351M | EV / Sales 2024 * | 9.31 x |
Net cash position 2024 * | 1.26B 1.72B | Net cash position 2025 * | 475M 648M | EV / Sales 2025 * | 8.06 x |
P/E ratio 2024 * |
-41.8
x | P/E ratio 2025 * |
-79.3
x | Employees | 2,100 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.59% |
Latest transcript on Alnylam Pharmaceuticals, Inc.
1 day | -1.06% | ||
1 week | -1.08% | ||
Current month | +2.67% | ||
1 month | +2.77% | ||
3 months | -6.25% | ||
6 months | -9.29% | ||
Current year | -22.79% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 61 | 16-09-18 | |
Jeffrey Poulton
DFI | Director of Finance/CFO | 56 | 19-08-12 |
Piyush Sharma
CMP | Compliance Officer | - | 22-09-20 |
Members of the board | Title | Age | Since |
---|---|---|---|
David Pyott
BRD | Director/Board Member | 70 | 15-12-17 |
Charles Sigal
BRD | Director/Board Member | 72 | 22-08-21 |
Margaret Hamburg
BRD | Director/Board Member | 68 | 19-01-09 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
5.08% | 1 M€ | 0.00% | - | |
4.04% | 2 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
24-05-24 | 147.8 | -1.08% | 506,806 |
24-05-23 | 149.4 | -1.01% | 500,527 |
24-05-22 | 150.9 | +0.86% | 350,723 |
24-05-21 | 149.6 | -0.41% | 448,620 |
24-05-20 | 150.2 | +0.56% | 368,554 |
Delayed Quote Nasdaq, May 24, 2024 at 04:00 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-22.79% | 18.9B | |
+67.53% | 62.86B | |
-0.77% | 41.38B | |
+45.66% | 40.38B | |
-10.72% | 27.64B | |
+13.30% | 26.46B | |
+4.70% | 12.67B | |
+24.10% | 12.27B | |
+27.41% | 12.07B | |
-8.12% | 11.21B |
- Stock Market
- Equities
- ALNY Stock